Qsemble Capital Management LP acquired a new position in shares of Royalty Pharma PLC (NASDAQ:RPRX – Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 74,416 shares of the biopharmaceutical company’s stock, valued at approximately $2,875,000.
Other hedge funds have also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC grew its holdings in Royalty Pharma by 868.1% during the 3rd quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 790 shares during the last quarter. Private Trust Co. NA grew its holdings in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 288 shares during the last quarter. Larson Financial Group LLC grew its holdings in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock worth $45,000 after acquiring an additional 306 shares during the last quarter. Richardson Financial Services Inc. bought a new stake in Royalty Pharma during the 3rd quarter worth about $54,000. Finally, Fifth Third Bancorp grew its holdings in Royalty Pharma by 16.9% during the 3rd quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after acquiring an additional 362 shares during the last quarter. Institutional investors own 54.35% of the company’s stock.
Analyst Upgrades and Downgrades
RPRX has been the topic of a number of research reports. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a research report on Thursday, February 12th. UBS Group upped their target price on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Morgan Stanley upped their target price on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a research report on Friday, April 10th. Weiss Ratings upgraded shares of Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, May 1st. Finally, TD Cowen restated a “buy” rating on shares of Royalty Pharma in a research report on Friday, February 27th. Seven investment analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $53.71.
Royalty Pharma Stock Performance
Royalty Pharma stock opened at $52.85 on Friday. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. Royalty Pharma PLC has a 1 year low of $32.15 and a 1 year high of $53.47. The company has a market cap of $30.43 billion, a PE ratio of 35.95, a PEG ratio of 1.45 and a beta of 0.40. The company’s 50-day moving average is $48.31 and its two-hundred day moving average is $43.35.
Royalty Pharma (NASDAQ:RPRX – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. The business had revenue of $631.00 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a net margin of 33.88% and a return on equity of 29.25%. Equities analysts anticipate that Royalty Pharma PLC will post 5.05 earnings per share for the current year.
Royalty Pharma Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be given a $0.235 dividend. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.8%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio (DPR) is currently 63.95%.
Insider Activity at Royalty Pharma
In related news, EVP Marshall Urist sold 13,684 shares of the stock in a transaction that occurred on Thursday, May 14th. The shares were sold at an average price of $53.06, for a total value of $726,073.04. Following the sale, the executive vice president directly owned 31,881 shares in the company, valued at $1,691,605.86. This trade represents a 30.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 34,791 shares of the stock in a transaction that occurred on Tuesday, April 28th. The shares were sold at an average price of $49.78, for a total transaction of $1,731,895.98. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 155,893 shares of company stock worth $7,512,360 in the last ninety days. Company insiders own 18.84% of the company’s stock.
About Royalty Pharma
Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.
The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.
Featured Articles
- Five stocks we like better than Royalty Pharma
- 3 Stocks to Own If Gas Prices Keep Rising
- 3 Crucial Aerospace Component Makers That Analysts Love
- Alphabet’s Googlebook Brings Gemini AI to PC Hardware
- Peloton Stock Gives Back Gains After Upbeat Earnings Report
Want to see what other hedge funds are holding RPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Royalty Pharma PLC (NASDAQ:RPRX – Free Report).
Receive News & Ratings for Royalty Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Royalty Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
